Endo Announces Issuance of Vasostrict® Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Endo's (ENDP) Vasostrict Patent News Seen as 'Important Development' at Deutsche Bank
June 28, 2016 3:20 PM EDTDeutsche Bank maintained a Buy rating on Endo International plc (NASDAQ: ENDP) with a price target of $30. Earlier the company announced that one of its operating companies, Par Pharmaceutical, was issued a new patent relating to Vasostrict 20 units/mL. Analyst
Gregg Gilbert said this was an important development and could help protect a key franchise.
"Vasostrict is a ~$300mn drug (~8% of total revenue), and risk... More
Endo International (ENDP) Vasostrict IP Adds Few Years of Exclusivity - Leerink
June 28, 2016 2:17 PM EDTLeerink Partners analyst Jason Gerberry weighed in on Endo International plc (NASDAQ: ENDP) after the company received issuance of US patent #9,375,478, which according to the analyst, at a minimum adds a few year to the firm's Vasostrict exclusivity assumption. While the bull case includes possible major price revision and significantly longer exclusivity,... More
Endo Int'l (ENDP) Vasostrict Patent News Negativly Impacts the Short Thesis - Mizuho
June 28, 2016 1:23 PM EDTMizuho analyst Irina Koffler weighed in on Endo Int'l (NASDAQ: ENDP) after the company announced that Vasostrict patent (9,375,478) that expires in Jan 2035, and has been submitted to FDA's Orange Book.
Koffler notes the drug represents approximately $300M in revenues to Endo,... More
Endo Int'l (ENDP) Surges on New Vasostrict Patent
June 28, 2016 12:50 PM EDTEndo Int'l (NASDAQ: ENDP) is surging 17% after the company announced that one of its operating... More
